Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Stroke Research and Treatment · 2026-01 · 2026 (1)
DOI: 10.1155/srat/7411011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stroke Research and Treatment, online erschienen am 09.05.2026. Verfasst von Abdullah Faiz Zaihan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shah Alam Hospital, Shah Alam, Malaysia. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Ticagrelor, a direct‐acting P2Y 12 receptor antagonist, has been proposed as an alternative to clopidogrel or aspirin for secondary prevention in patients with acute ischemic stroke or transient ischemic attack (TIA). However, its clinical utility remains uncertain due to variable trial findings and safety concerns. This study is aimed at evaluating the efficacy and safety of ticagrelor compared to clopidogrel or aspirin in reducing recurrent stroke and major bleeding in patients with noncardioembolic acute ischemic stroke or TIA.
Methods
A systematic search of PubMed, Embase, CENTRAL, and Chinese databases was conducted to identify randomized controlled trials comparing ticagrelor with aspirin or clopidogrel in this population. The primary outcomes were recurrent stroke and major bleeding. Random‐effects meta‐analyses were performed, and heterogeneity was assessed using the I 2 statistic.
Results
Six randomized controlled trials were included. Ticagrelor significantly reduced the risk of recurrent stroke compared to control (pooled OR: 0.78; 95% CI: 0.70–0.89; I 2 = 9 % ). No significant increase in major bleeding was observed (OR: 0.92; 95% CI: 0.66–1.28; I 2 = 0 % ). Risk of bias was low in two trials and raised some concerns in the remaining four due to open‐label designs or limited reporting.
Conclusion
Ticagrelor offers superior efficacy over clopidogrel or aspirin in preventing recurrent stroke, with no excess risk of major bleeding. It may be particularly beneficial in patients with poor clopidogrel metabolism or high recurrence risk. Further research is needed to establish its long‐term safety, cost‐effectiveness, and optimal use in clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Shah Alam Hospital, Shah Alam, Malaysia.
- School of Pharmacy, IMU University, Kuala Lumpur, Malaysia, imu.edu.my.
- School of Applied Sciences, University of Huddersfield, Huddersfield, UK, hud.ac.uk.
ORCID-Profile: Kaeshaelya Thiruchelvam, Chia Siang Kow
Zitieren
APA
Zaihan, A. F., Mohamad Hafiz, N. A. H., Tong, Y. S., Thiruchelvam, K., & Kow, C. S. (2026). Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Stroke Research and Treatment, 2026(1). https://doi.org/10.1155/srat/7411011
Vancouver
Zaihan AF, Mohamad Hafiz NAH, Tong YS, Thiruchelvam K, Kow CS. Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Stroke Research and Treatment. 2026;2026(1). doi:10.1155/srat/7411011
BibTeX
@article{Zaihan2026,
author = {Zaihan, Abdullah Faiz and Mohamad Hafiz, Nurul Ameera Huda and Tong, Yee Sheun and Thiruchelvam, Kaeshaelya and Kow, Chia Siang},
title = {Ticagrelor Versus Clopidogrel or Aspirin in Secondary Stroke Prevention: Systematic Review and Meta‐Analysis of Randomized Controlled Trials},
journal = {Stroke Research and Treatment},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/srat/7411011}
}
EUVIMED